Disopyramide, a Class IA antiarrhythmic drug, carries a broad range of side effects dominated by anticholinergic symptoms like dry mouth, constipation, and urinary retention, along with more serious cardiovascular risks including dangerously low blood pressure and a specific type of irregular heartbeat called torsades de pointes. These effects stem from the drug’s dual action on both the heart’s electrical system and the body’s acetylcholine signaling, making it one of the more side-effect-heavy antiarrhythmic options still in clinical use.
Anticholinergic Effects Are the Most Common Problem
The side effects that drive the most day-to-day complaints from people taking disopyramide are anticholinergic in nature. Acetylcholine is a chemical messenger involved in digestion, urination, saliva production, and focusing the eyes, among other things. Disopyramide blocks some of those signals, which leads to a predictable cluster of symptoms: dry mouth, blurred vision, constipation, and difficulty urinating. These are the same types of effects you get from medications like atropine, and research has confirmed that the degree of anticholinergic activity in a patient’s blood correlates directly with how much disopyramide is circulating.1PubMed Central. Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy The drug’s main metabolite adds to this effect, meaning both the parent drug and what your body converts it into contribute to these symptoms.
For many people, these effects are more annoying than dangerous. Dry mouth is uncomfortable, blurred vision can be alarming, and constipation is a nuisance. But in certain cases, anticholinergic effects cross the line from inconvenience to medical emergency. Urinary retention, where the bladder cannot empty properly, has been documented repeatedly. One case series reported nine patients who developed urinary retention on disopyramide, including one who progressed to acute kidney injury because urine backed up and damaged the kidneys.2PubMed. Disopyramide-induced urinary retention. Report of nine cases and review of the literature Men with enlarged prostates are particularly vulnerable, since the drug compounds an existing mechanical obstruction.
In a multicenter study of patients with obstructive hypertrophic cardiomyopathy, about a third of those started on disopyramide eventually needed to switch to a different treatment or undergo a procedure, and anticholinergic side effects were among the reasons for discontinuation.3PubMed. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy These effects tend to be dose-related, so lowering the dose sometimes helps, but for some patients the therapeutic window is narrow enough that reducing the dose also reduces the drug’s effectiveness.
Cardiovascular Side Effects
Disopyramide works by blocking sodium channels in the heart, which slows electrical conduction and helps suppress abnormal rhythms. But it also blocks potassium channels, specifically the HERG channel that is critical for the heart to reset between beats. Laboratory studies have shown that disopyramide inhibits HERG-encoded potassium currents at concentrations well within the normal therapeutic range.4Biochemical and Biophysical Research Communications. Inhibition of HERG Potassium Channel Current by the Class 1a Antiarrhythmic Agent Disopyramide This potassium channel blockade delays the heart’s electrical recovery, which shows up on an ECG as QT prolongation.
QT prolongation matters because it sets the stage for torsades de pointes, a fast, chaotic heart rhythm that can cause fainting, seizures, or cardiac arrest. Disopyramide is classified alongside quinidine and procainamide as being “strongly concordant” with the production of torsades de pointes among antiarrhythmic drugs.5PubMed. Antiarrhythmic drugs and torsade de pointes The risk does not scale neatly with how much the QT interval extends on the ECG; some patients develop torsades at only modestly prolonged intervals while others tolerate greater prolongation without incident. This unpredictability is part of what makes the drug tricky to manage.
A case report of a patient with myasthenia gravis who was given disopyramide illustrates how multiple effects can pile up at once. The patient developed QT prolongation and torsades de pointes alongside severe respiratory failure as the drug worsened her underlying neuromuscular disease.6PubMed. Severe respiratory failure and torsades de pointes induced by disopyramide in a patient with myasthenia gravis That kind of stacking is rare, but it underscores why prescribers need a full picture of a patient’s health before starting the drug.
Negative Inotropic Effect
Among the Class IA antiarrhythmics, disopyramide stands out for having the strongest tendency to reduce the heart’s pumping force. In laboratory experiments on human heart muscle, the drug produced a clear, dose-dependent reduction in how forcefully the muscle contracted.7JACC: Basic to Translational Science. Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study For someone with a healthy heart, this effect is usually manageable. But in patients with pre-existing heart failure or poor left ventricular function, the added depression of pumping strength can push the heart into a dangerous state, potentially causing worsening heart failure or severe low blood pressure.
Ironically, this negative inotropic property is precisely why disopyramide is valued in obstructive hypertrophic cardiomyopathy: reducing the force of contraction helps relieve the obstruction within the thickened heart. In that specific disease context, the side effect becomes the treatment. Everywhere else, it is a liability.
“Disopyramide Syncope”
There is a recognized phenomenon sometimes called “disopyramide syncope,” where a person faints unexpectedly at what should be a safe blood level of the drug. This can happen because of a sudden dip in blood pressure, an arrhythmia episode, or a combination of both. The unpredictability of these events means that patients starting disopyramide usually need close ECG monitoring, especially in the first days and whenever the dose is adjusted.
Hypoglycemia
One of the more surprising and underappreciated side effects of disopyramide is hypoglycemia, meaning blood sugar that drops low enough to cause symptoms like shakiness, confusion, sweating, or even loss of consciousness. This happens because disopyramide can block ATP-sensitive potassium channels on pancreatic beta cells, the same type of channel that diabetes drugs called sulfonylureas target to stimulate insulin release.8PubMed. Disopyramide-induced hypoglycemia in a non-diabetic hemodialysis patient: a case report and review of the literature In other words, disopyramide can accidentally trigger insulin secretion even when blood sugar is normal or already low.
The danger is particularly acute when disopyramide is combined with sulfonylurea diabetes medications. Laboratory channel recordings have shown that when disopyramide and a sulfonylurea like glimepiride are applied together, they shut down roughly 95% of the relevant potassium channels, far more than either drug alone.9PubMed. Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes That level of channel inhibition is more than enough to trigger a massive insulin surge, which can send blood sugar plummeting. Patients with diabetes who take both drugs concurrently need to be especially vigilant about monitoring their glucose levels. But hypoglycemia from disopyramide has also been reported in people who do not have diabetes at all, including dialysis patients, which means the risk is not limited to those with metabolic diseases.
Older adults, people who are malnourished, and those with liver or kidney problems are at elevated risk because the drug lingers in the body longer and the usual counterbalancing responses to low blood sugar may be blunted. Severe hypoglycemia from disopyramide has been described as unpredictable, which makes it especially dangerous: by the time symptoms appear, blood sugar may already be critically low.
Kidney Impairment Changes the Risk Equation
Disopyramide is cleared partly through the kidneys, and kidney impairment meaningfully changes how the drug behaves in the body. Studies of patients with reduced kidney function found that the drug’s elimination half-life increases substantially when kidney filtration drops. One study calculated a mean half-life of about 12.7 hours in patients with impaired kidneys, considerably longer than what is typically seen in healthy individuals.10PubMed Central. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment A separate study found that meaningful slowing of elimination does not kick in until kidney filtration (measured by creatinine clearance) falls below about 40 mL per minute, but below that threshold there is a clear, linear relationship between worsening kidney function and slower drug clearance.11PubMed. Disposition kinetics of disopyramide in patients with renal insufficiency
The practical takeaway is that people with moderate-to-severe kidney disease need lower starting and maintenance doses of disopyramide, and ideally should have their blood levels of the drug measured to prevent accumulation. Both the drug itself and its active metabolite build up when the kidneys cannot clear them efficiently, which amplifies every side effect described above: more anticholinergic burden, greater risk of QT prolongation, a higher chance of hypoglycemia, and a stronger negative inotropic effect. Because the drug’s volume of distribution is also reduced by about a third in these patients, even the initial loading dose needs to be cut.12PubMed. Disposition kinetics of disopyramide in patients with renal insufficiency
What Happens in an Overdose
Acute disopyramide overdose can be life-threatening. The primary dangers are severe disturbances in the heart’s electrical conduction and dangerously low blood pressure, often accompanied by central nervous system toxicity such as confusion, agitation, or seizures.13PubMed. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide The combination of a weakened heartbeat (the negative inotropic effect pushed to extremes) and a fast or chaotic rhythm can lead to cardiogenic shock, where the heart cannot pump enough blood to sustain the body’s organs.
Treatment in the emergency setting focuses on gut decontamination if the patient presents soon after ingestion, respiratory support, and immediate management of seizures if they occur. Intravenous fluids and vasopressors may be needed to support blood pressure. Cardiac monitoring is essential because the heart rhythm can deteriorate rapidly. There is no specific antidote for disopyramide poisoning, so management is supportive: keep the heart beating, keep the blood pressure up, control seizures, and wait for the drug to clear. In patients with very poor kidney function, clearance takes longer, which extends the danger window.
Long-Term Safety in Hypertrophic Cardiomyopathy
Disopyramide has experienced something of a renaissance in the treatment of obstructive hypertrophic cardiomyopathy, where its negative inotropic effect is actually the therapeutic goal. That has generated more recent long-term safety data than exists for its use in ordinary arrhythmia management. A study of patients treated with disopyramide for at least five years found that ventricular arrhythmias and weakening of the heart’s pumping function were uncommon and were not attributed to the drug. Death while on disopyramide was exceedingly rare in this cohort, occurring in only three patients, all of whom were over 90 years old and died of causes unrelated to their heart condition.14PubMed Central. Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years
In the earlier multicenter study, the all-cause cardiac death rate did not differ significantly between patients managed with disopyramide and those who went on to other treatments, at roughly 1.4% versus 2.6% per year.15PubMed. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy Sudden death rates were similarly comparable between the two groups. These data suggest that when disopyramide is used in the specific context of hypertrophic cardiomyopathy, it does not appear to increase the risk of dying from cardiac causes over the long haul, even though the drug carries real risks of side effects and a meaningful proportion of patients eventually discontinue it.
Data in children are more limited but broadly encouraging. A study of pediatric patients with obstructive hypertrophic cardiomyopathy reported that about 18% experienced side effects, and roughly a third saw their symptoms return or worsen enough to require a change in medication or surgical intervention.16International Journal of Cardiology. Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy The side-effect rate in children was somewhat lower than in adults, but the drug is not a permanent fix for everyone: some children outgrow the benefit and need further treatment as they grow.
Who Should Be Especially Cautious
Several groups face amplified risk when taking disopyramide, and the reasons differ from group to group:
- Older adults: Anticholinergic burden is more dangerous as people age. Cognitive effects like confusion can be mistaken for dementia, urinary retention is more common in men with prostate enlargement, constipation can progress to bowel obstruction, and falls from dizziness or syncope carry higher consequences.
- People with heart failure: The negative inotropic effect can tip a compromised heart into decompensation. Disopyramide is generally avoided in patients with reduced ejection fraction unless the clinical scenario specifically calls for it, as in certain forms of hypertrophic cardiomyopathy.
- Patients with kidney disease: As covered above, drug accumulation magnifies all side effects and requires dose reduction below a creatinine clearance of about 40 mL per minute.
- People taking sulfonylureas: The interaction at the potassium channel level can cause severe, unpredictable hypoglycemia that demands close glucose monitoring.
- Patients with myasthenia gravis: Disopyramide can worsen neuromuscular weakness, and case reports have documented respiratory failure in this population.17PubMed. Severe respiratory failure and torsades de pointes induced by disopyramide in a patient with myasthenia gravis
- People with glaucoma: The anticholinergic effects can raise intraocular pressure in those with narrow-angle glaucoma, potentially triggering an acute crisis.
If you fall into one of these categories and have been prescribed disopyramide, you are not necessarily unable to take it, but you and your prescriber need to weigh the risks more carefully and monitor more closely. For most of these groups, the concern is not a hypothetical worst case but a documented pattern of adverse events.
Side Effects Versus Newer Alternatives
Disopyramide has been around since the 1970s, and its side-effect profile reflects the era’s tolerance for anticholinergic burden. For general arrhythmia management, it has largely been supplanted by newer antiarrhythmics that carry fewer anticholinergic effects and less negative inotropy. The drug’s main remaining role is in obstructive hypertrophic cardiomyopathy, where its particular combination of sodium channel blockade and contractility reduction is therapeutically useful.
Even within that niche, a new generation of cardiac myosin inhibitors has begun to challenge disopyramide’s position. These newer agents target the contractile machinery of the heart muscle more directly and avoid the anticholinergic baggage entirely. Whether they will fully replace disopyramide remains to be seen, as long-term safety data are still accumulating for those drugs. For now, disopyramide remains a frontline option in hypertrophic cardiomyopathy, partly because decades of clinical experience have mapped its risks thoroughly. The side effects are real, sometimes serious, and occasionally dangerous, but they are also well characterized. That predictability, combined with routine monitoring and dose adjustment, allows many patients to stay on the drug effectively for years.